Influenza Vaccines for the World

2-4 April 2019, Royal College of Physicians of Edinburgh, Edinburgh, Scotland, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day Three

Final Conference Programme | Thursday 4th April 2019

SESSION 10:
General – I

Moderator: Manon Cox (NextWaveBio, East Haven, Connecticutt, USA)

09.00-09.20
‘Safety and immunogenicity of the Polyoxidonium®-adjuvanted subunit influenza vaccine. A systematic review and meta-analysis of clinical trials’
R. Kompier and W.E. Beyer (FluConsult, Noordwijk, The Netherlands)

09.20-09.40
‘Polyoxidonium”-based low-dose “Grippol® Quadrivalent” vaccine effectively stimulates dendritic cells maturation and immune response’
V.Yu. Talayev1, A.V. Matveichev2, N.V. Volkova2, I.E. Zaichenko1, M.V. Talaeva1, V.F. Ostrov2, O.N. Babaykina1, E.V. Voronina1 and O.I. Orekhova2 (1 Federal Budget Institution of Science, Nizhny Novgorod Scientific and Research Institute of Epidemiology and Microbiology I.N. Blokhina, Federal Service on Surveillance for Consumer Rights Protection and Human Welfare (Rospotrebnadzor), Moscow, Russia; 2 NPO Petrovax Pharm, LLC, Podolsk, Moscow Region, Russia)

09.40-10.00
‘DNA vaccination with HLAII-targeted hemagglutinin to quench an emerging pandemic threat’
Tor Kristian Andersen1, Gunnveig Grødeland1, Agnete B. Fredriksen2 and Bjarne Bogen1 (1 K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway; 2 Vaccibody AS, Oslo, Norway)

10.00-10.20
‘OVX836, a multimerized nucleoprotein-based vaccine candidate protects mice against lethal challenge with multiple strains of influenza A viruses’
Alexandre Le Vert1, Judith Del Campo1, Andrés Pizzorno2, Marion Chevandier1, Marjorie Haller1, Julien Bouley1, Thomas Julien2, Guy Boivin3, Marie-Eve Hamelin3, Florence Nicolas1, Manuel Rosa-Calatrava2 and Fergal Hill1 (1 Osivax, Lyon, France; 2 Virologie et Pathologie Humaine – VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon, Université de Lyon, Lyon, France; 3 Centre de Recherche en Infectiologie of the Centre Hospitalier Universitaire de Québec and Université Laval, Québec, Canada)

10.20-10.40
Coffee Break & Posters

SESSION 11:
General – II

Moderator: To be confirmed

10.40-11.00
‘Nanofibres for non-invasive sublingual immunisation against influenza and results on mouse and pig models’
Jaroslav Turánek (Veterinary Research Institute, Brno, Czech Republic)

11.00-11.20
‘Development of a nanoparticle universal influenza vaccine’
Vira Bitko1, Andrea Harris1, Spencer Stonier1, Thomas Hickey1, Anesu Nyawata1, Zhidong Ma1, Ravi Anantha1, Vladimir Savransky1, Jeff Welch1, Brett Hurst2, Bart Tarbet2, Michael Lacy1 and Kelly Warfield1 (1 Emergent BioSolutions, Gaithersburg, Maryland, USA; 2 Utah State University, Logan, Utah, USA)

11.20-11.40
‘Development of replication-limited influenza vaccine virus’
Wenjun Liu (Chinese Academy of Sciences, Beijing, PR China)

11.40-12.00
‘SEC meets TRPS: Automated isolation and high-precision analysis of viruses’

Camille Roesch, Murray J.Broom, Anoop K.Pal and H.J Van Der Voorn (Izon Science, Bioparc Laennec, Lyon, France)

12.00-13.00
Lunch Break & Posters

SESSION 12: SPECIAL SESSION: INFLUENZA VACCINES FROM RUSSIA

Moderator: Yuri Vasiliev (Research Institute of Ultrapure Biologicals, St. Petersburg, Russian Federation)

13.00-13.30
‘Influenza vaccines from Russia: A historical overview and recent developments’
Yuri Vasiliev (Research Institute of Ultrapure Biologicals, St. Petersburg, Russian Federation)

13.30-13.50
‘Flu-M: A new family of Russian influenza vaccines’
E.N. Zhirenkina (Research Institute of Vaccines and Sera, St. Petersburg, Russia)

13.50-14.10
‘Russian influenza vaccines: Overseas technology transfer and immunization experience in the LAC region’
S.V. Uiba and E.P. Nacharova (MECHNIKOV / Latin-American Institute of Biotechnology)

14.10-14.30
Tea Break & Posters Breakdown

SESSION 13:
CLOSING PLENARY

Moderator: John Oxford (Blizzard Institute, Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)

14.30-15.00
‘Are there good reasons to recommend paediatric influenza vaccination for all children in Europe?’
Dirk Poelart (GSK Vaccines, Wavre, Belgium)

15.00-15.30
‘IFPMA presentation: The delay in H3N2 recommendation for the Northern hemisphere 2019-2020 season: What this actually means (possible vaccine availability delays), how to deal with it this in time and strategically’
IFPMA Speaker to be confirmed

15.30-15.50
‘Influenza: Why vaccine uptake matters’
Bram Palache (IFPMA/FluPal Consultancy BV, Amstelveen, The Netherlands)

15.50-16.00
Closing Remarks

Departure

* This final programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.

 

IVW 2019 Delegates

Login details will be supplied after you have registered for the event.


IVW 2019 Sponsors

  • Izon Science
  • hVIVO
  • MedImmune
  • NanoPass
  • Vaxxas
  • SPbSRIVS
  • Vismederi
  • BiondVax
  • Medicago
  • Inovio Pharmaceuticals
  • isirv
  • Vaxart
  • FluConsult
  • InDevR
  • APACI
  • Janssen
  • Novavax
  • Sanofi Pasteur
  • Eurocine Vaccines

IVW 2019 Downloads

IVW 2019 Leaflet

IVW 2019 Mailing List

Name
E-mail Address
What is 3+2-1?